Navigation Links
Personalized medicine: Molecular imaging predicts treatment success in many cancers
Date:9/1/2010

Reston, Va. A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

According to researchers, molecular imaging allows physicians to identify the severity and extent of disease and, in turn, provide patients with personalized care. In addition, molecular imaging allows doctors to see how effective a treatment is early in the process so that changes can be made to ensure the best treatment for each individual patient.

"For patients with thyroid cancer, 'one size fits all' no longer applies," said Ravinder Grewal, M.D., corresponding author of "The Effect of Posttherapy 131I- SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer" and an assistant attending physician in nuclear medicine at Memorial Sloan-Kettering Cancer Center in New York. "Through molecular imaging, the paradigm is changing toward more tailored and customized management of treatment. As a result, we can see how far a disease has spread and spare the patient from additional examination, time and radiation exposure."

For the study, researchers performed planar imaging and single-photon emission computed tomography (SPECT)/CT on 148 patients with thyroid cancer. The results showed that SPECT/CT provided information that reduced the need for additional cross-sectional imaging in 29 patients and redefined the initial risk of recurrence estimates in seven of 109 patients, thereby altering patient management recommendations in terms of frequency and intensity of follow-up studies.

In another study, researchers in Germany used positron emission tomography (PET)/CT with the radiotracer 68Ga-DOTATATE to evaluate the effectiveness of molecular imaging in monitoring patients with neuroendocrine tumors after undergoing peptide receptor radionuclide treatment. This study evaluated 33 patients at baseline and three months after treatment began. The findings suggest that PET/CT may contribute to the early prediction of treatment outcome in patients with neuroendocrine tumors.

"This molecular imaging technique can help doctors to classify patients according to their prognosis and to choose a personalized follow-up strategy," said Alexander Haug, M.D., corresponding author of the study and a researcher at Ludwig-Maximilians-University, Munich, Germany. "With the use of specific biomarkers, nuclear medicine provides the unique opportunity to perform diagnosis and therapy with the same tracer compound andwith the use of different biomarkersto provide personalized tissue characterization. Nuclear medicine will be essential for the work-up of cancer patients in the near future."

The third study also used molecular imaging to monitor treatment success and aid in planning. Researchers evaluated 104 patients with newly diagnosed Hodgkin lymphoma using fluorodeoxyglucose (FDG) PET after undergoing two cycles of chemotherapy treatment. Of these patients, 93 achieved complete remission after first-line therapy. During a median follow-up of 36 months, relapse or disease progression was seen in 22 patients. Researchers found that PET is an accurate and independent predictor of event-free survival in Hodgkin lymphoma patients.

"Our findings suggest that early interim FDG-PET may play a pivotal role in Hodgkin lymphoma treatment, tailoring the therapy to an individual level, providing a less toxic treatment for patients with a low risk of failure while attempting treatment intensification for patients regarded as high risk of failure on the basis of the PET findings," said Juliano Cerci, M.D., Division of Nuclear Medicine, Heart Institute (InCor), Medical School of the University of So Paulo, Brazil, and corresponding author of "18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma."

The fourth study investigated the role of 18F-FDG PET/CT for the early identification of response to therapy in patients with non-small cell lung cancer (NSCLC). Researchers studied 23 NSCLC patients who were treated with a molecular-targeted agent called epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and used 18F-FDG PET/CT to monitor the disease before and at one week after administration of EGFR-TKI. Changes in tumor 18F-FDG uptake during treatment were measured by standardized uptake values. Six patients experienced partial response, while 16 patients had stable disease and one patient had progressive disease. The results of the study suggest that early during the course of therapy, 18F-FDG PET/CT can predict response to treatment in patients with NSCLC.

According to researchers, monitoring a patient's response to treatment can avoid unnecessary toxicity, as well as the cost of ineffective treatment. They also state that the results of the study are promising and consistent with the results of preclinical studies.


'/>"/>

Contact: Amy Shaw
ashaw@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. GUMCs Lombardi Hosts Symposium Exploring Future of Cancer Research and Personalized Medicine
2. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
3. DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health
4. Personalized Live on-Demand Yoga Avatar Gains Popularity Amongst Users, Across all age Groups
5. Small Nutritional Changes are a Key to Health, Weight Loss, says DSM Personalized Nutrition
6. TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
7. Personalized medicine for cancer patients in a new technology era
8. Pediatric personalized medicine takes center stage at first-of-its-kind international conference
9. DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs
10. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
11. Advances in personalized medicine take center stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... ... Nutrition Education for the Public (NEP), a dietetic practice ... Nutrition Partnership (SNP) in presenting “Eating Heart Healthy: Exploring Issues of Low Seafood ... inform consumers about the health benefits of eating a seafood-rich diet. , ...
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... organizations submitted a letter to President Trump expressing their support for an independent ... doctors, two Ph.D. scientists and one medical journalist, will hold a press conference ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has named ... more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers a ... cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box blades. ...
(Date:3/29/2017)... York City, NY (PRWEB) , ... March 29, ... ... body for men’s and women’s professional squash, announced it has enlisted New York ... partner. The agency will develop and procure sponsorship opportunities for the Professional ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... SAN DIEGO , March 29, 2017 Avelas Biosciences, ... care from diagnosis through treatment, today announced that Carmine N. ... of the company at the Needham & Company 16 th ... EDT (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... Biosciences ...
(Date:3/29/2017)... Today, CVS Health officials (NYSE: CVS ... of Public Health Director Gerd Clabaugh and Office ... announcing the availability of the opioid overdose-reversal medicine naloxone without ... Health has established a standing order with physicians in ... access to the medication in the state.   ...
(Date:3/29/2017)... WALNUT CREEK, Calif. , Mar 29, 2017 ... tissue-sparing, cervical-fusion technology, announced the addition of two ... Scott Lynch has joined the company to ... is assuming International leadership.  Together, Mr. Lynch and ... industry experience.  Mr. Lynch joins ...
Breaking Medicine Technology: